These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21160462)

  • 1. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.
    Najafian B; Svarstad E; Bostad L; Gubler MC; Tøndel C; Whitley C; Mauer M
    Kidney Int; 2011 Mar; 79(6):663-670. PubMed ID: 21160462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.
    Najafian B; Tøndel C; Svarstad E; Gubler MC; Oliveira JP; Mauer M
    J Am Soc Nephrol; 2020 Apr; 31(4):865-875. PubMed ID: 32127409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.
    Mauer M; Glynn E; Svarstad E; Tøndel C; Gubler MC; West M; Sokolovskiy A; Whitley C; Najafian B
    PLoS One; 2014; 9(11):e112188. PubMed ID: 25386848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.
    Najafian B; Tøndel C; Svarstad E; Sokolovkiy A; Smith K; Mauer M
    PLoS One; 2016; 11(4):e0152812. PubMed ID: 27081853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.
    Najafian B; Silvestroni A; Sokolovskiy A; Tøndel C; Svarstad E; Obrisca B; Ismail G; Holida MD; Mauer M
    Kidney Int; 2022 Jul; 102(1):173-182. PubMed ID: 35483528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
    Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
    Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
    Wijburg FA; Bénichou B; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini C; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymańska A; Ramaswami U
    PLoS One; 2015; 10(5):e0124987. PubMed ID: 25955246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
    Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
    J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
    Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
    J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.
    Skrunes R; Svarstad E; Kampevold Larsen K; Leh S; Tøndel C
    Nephrol Dial Transplant; 2017 May; 32(5):807-813. PubMed ID: 27190352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
    Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bedside Stereomicroscopy of Fabry Kidney Biopsies: An Easily Available Method for Diagnosis and Assessment of Sphingolipid Deposits.
    Svarstad E; Leh S; Skrunes R; Kampevold Larsen K; Eikrem Ø; Tøndel C
    Nephron; 2018; 138(1):13-21. PubMed ID: 28848191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy.
    Fall B; Scott CR; Mauer M; Shankland S; Pippin J; Jefferson JA; Wallace E; Warnock D; Najafian B
    PLoS One; 2016; 11(12):e0168346. PubMed ID: 27992580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of DENDRIN in several glomerular diseases and correlation to pathological parameters and renal failure - preliminary study.
    Mizdrak M; Vukojević K; Filipović N; Čapkun V; Benzon B; Durdov MG
    Diagn Pathol; 2018 Nov; 13(1):90. PubMed ID: 30458823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).
    Fogo AB; Bostad L; Svarstad E; Cook WJ; Moll S; Barbey F; Geldenhuys L; West M; Ferluga D; Vujkovac B; Howie AJ; Burns A; Reeve R; Waldek S; Noël LH; Grünfeld JP; Valbuena C; Oliveira JP; Müller J; Breunig F; Zhang X; Warnock DG;
    Nephrol Dial Transplant; 2010 Jul; 25(7):2168-77. PubMed ID: 19833663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrastructural changes in the glomerular filtration barrier and occurrence of proteinuria in Chinese patients with type 2 diabetic nephropathy.
    Zhu WW; Chen HP; Ge YC; Xie HL; Zeng CH; Li LS; Liu ZH
    Diabetes Res Clin Pract; 2009 Dec; 86(3):199-207. PubMed ID: 19815303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.
    Weil EJ; Lemley KV; Mason CC; Yee B; Jones LI; Blouch K; Lovato T; Richardson M; Myers BD; Nelson RG
    Kidney Int; 2012 Nov; 82(9):1010-7. PubMed ID: 22718189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
    Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
    Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.
    Kanai T; Ito T; Odaka J; Saito T; Aoyagi J; Betsui H; Yamagata T
    Eur J Pediatr; 2016 Mar; 175(3):427-31. PubMed ID: 26454753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.